The present invention relates to photoactivatable compounds and methods of use thereof for determining binding site and other structural information about RNA transcripts. The invention also provides methods of identifying RNA transcripts that bind compounds and are thus druggable, methods of screening drug candidates, and methods of determining drug binding sites and/or accessible or reactive sites on a target RNA.

The present invention relates to photoactivatable compounds and methods of use thereof for determining binding site and other structural information about RNA transcripts. The invention also provides methods of identifying RNA transcripts that bind compounds and are thus druggable, methods of screening drug candidates, and methods of determining drug binding sites and/or accessible or reactive sites on a target RNA.

The present invention relates to photoactivatable compounds and methods of use thereof for determining binding site and other structural information about RNA transcripts. The invention also provides methods of identifying RNA transcripts that bind compounds and are thus druggable, methods of screening drug candidates, and methods of determining drug binding sites and/or accessible or reactive sites on a target RNA.

The present invention relates to photoactivatable compounds and methods of use thereof for determining binding site and other structural information about RNA transcripts. The invention also provides methods of identifying RNA transcripts that bind compounds and are thus druggable, methods of screening drug candidates, and methods of determining drug binding sites and/or accessible or reactive sites on a target RNA.

A method for identifying a nucleic acid template that include (a) providing a plurality of primer-template hybrids, wherein a first hybrid of the plurality includes a first template hybridized to a first primer, and wherein a second hybrid of the plurality includes a second template hybridized to a second primer, the second primer having a ternary complex inhibitor moiety at the 3′ end; (b) delivering polymerases and nucleotides to the plurality, whereby the first hybrid binds a polymerase and nucleotide to form a stabilized ternary complex and whereby the second hybrid does not bind a polymerase and nucleotide to form a stabilized ternary complex; and (c) detecting the stabilized ternary complex to identify the first template.

The disclosure relates to antibody conjugates comprising an antibody linked to a polynucleotide, aptamer conjugates comprising an aptamer linked to a polynucleotide, and methods for detecting a marker or several markers in a sample by using said antibody and aptamer conjugates. The present disclosure also relates to microfluidics devices for detecting markers in a sample. The present disclosure further relates to methods for detecting a microorganism or several microorganisms in a sample and a microfluidics device to be used to detect such microorganisms.

The disclosure relates to antibody conjugates comprising an antibody linked to a polynucleotide, aptamer conjugates comprising an aptamer linked to a polynucleotide, and methods for detecting a marker or several markers in a sample by using said antibody and aptamer conjugates. The present disclosure also relates to microfluidics devices for detecting markers in a sample. The present disclosure further relates to methods for detecting a microorganism or several microorganisms in a sample and a microfluidics device to be used to detect such microorganisms.

The disclosure relates to antibody conjugates or aptamer conjugates comprising an antibody linked to a lipid vesicle comprising a detectable label, methods for detecting a marker or several markers in a sample by using said antibody and aptamer conjugates. The present disclosure further relates to microfluidics devices to detect one or more markers in a sample by using said antibody and aptamer conjugates.

The disclosure relates to antibody conjugates or aptamer conjugates comprising an antibody linked to a lipid vesicle comprising a detectable label, methods for detecting a marker or several markers in a sample by using said antibody and aptamer conjugates. The present disclosure further relates to microfluidics devices to detect one or more markers in a sample by using said antibody and aptamer conjugates.

Disclosed herein are biosensors, which may be made from cell lysates, purified enzymes, or a combination thereof, for testing for the presence of a pathogen, such as SARS-CoV-2. The biosensor may be used in the context of a paper-based test, such as a colorimetric COVID-19 test. Methods of using the biosensor are also disclosed.